Updated
Reviewed
Dec. 18, 2019
Appendix B: Drug Characteristics Tables
Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors
The older NRTIs ddI and d4T are no longer commonly used in clinical practice and have been removed from this table. Please refer to the July 10, 2019, version of the guidelines (found in the archived guidelines section of ClinicalInfo) or to the FDA product labels for ddI and d4T for information regarding these drugs.
| Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitorsa | |
|---|---|
Appendix B: Drug Characteristics Tables
Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors
The older NRTIs ddI and d4T are no longer commonly used in clinical practice and have been removed from this table. Please refer to the July 10, 2019, version of the guidelines (found in the archived guidelines section of ClinicalInfo) or to the FDA product labels for ddI and d4T for information regarding these drugs.
| Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitorsa | |
|---|---|
Download Guidelines
- Section OnlyPDF (298.54 KB)
- Full GuidelinePDF (2.44 MB)
- Recommendations OnlyPDF (229.24 KB)
- Tables OnlyPDF (939.48 KB)